| pubmed-article:19898989 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19898989 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19898989 | lifeskim:mentions | umls-concept:C0001206 | lld:lifeskim |
| pubmed-article:19898989 | lifeskim:mentions | umls-concept:C0209211 | lld:lifeskim |
| pubmed-article:19898989 | lifeskim:mentions | umls-concept:C0524527 | lld:lifeskim |
| pubmed-article:19898989 | lifeskim:mentions | umls-concept:C1280519 | lld:lifeskim |
| pubmed-article:19898989 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:19898989 | pubmed:dateCreated | 2010-4-19 | lld:pubmed |
| pubmed-article:19898989 | pubmed:abstractText | Surgical resection is often not curative in patients with acromegaly and long-acting somatostatin analogues (lanreotide or octreotide) are often needed. This study assessed the efficacy and safety of self- or partner-administration of lanreotide in patients with acromegaly. This was a six-month, single-arm, open-label study conducted at 13 endocrinology clinics. Fifty-nine patients received deep subcutaneous lanreotide injections every 28 days. Twelve patients started on 120 mg lanreotide and forty-seven started on 90 mg lanreotide. At week 16, the dose was adjusted to 60, 90 or 120 mg based on insulin-like growth factor-1 (IGF-1) levels at week 12. Fifty-nine patients with acromegaly either switched from long-acting octreotide (switch; n = 33) or were somatostatin analogue treatment-naïve or not currently taking long-acting octreotide ("other"; n = 26). The key endpoints included the percentage of patients/partners able to self- or partner-inject lanreotide and those with normal IGF-1 or growth hormone (GH) levels at week 24/early termination. 100% of patients/partners correctly self- (n = 41) or partner-injected (n = 18) lanreotide by week 4. By week 24/early termination, IGF-1 levels were controlled in 93.7% of switch and 46.2% of "other" patients, while GH levels were controlled in 76.9% and 39.1% of patients, respectively. Both IGF-1 and GH were controlled in 73.1% of switch and 30.4% of "other" patients. Most switch patients (81%) reported they preferred lanreotide over long-acting octreotide for future use (P = 0.0001). Self- or partner-administration of lanreotide is generally well tolerated and associated with IGF-1 and GH control in many lanreotide-naïve patients with acromegaly. | lld:pubmed |
| pubmed-article:19898989 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19898989 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19898989 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19898989 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19898989 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19898989 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19898989 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19898989 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19898989 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19898989 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19898989 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19898989 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19898989 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19898989 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19898989 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19898989 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19898989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19898989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19898989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19898989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19898989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19898989 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19898989 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:19898989 | pubmed:issn | 1573-7403 | lld:pubmed |
| pubmed-article:19898989 | pubmed:author | pubmed-author:MolitchMark... | lld:pubmed |
| pubmed-article:19898989 | pubmed:author | pubmed-author:SalvatoriRobe... | lld:pubmed |
| pubmed-article:19898989 | pubmed:author | pubmed-author:BonertVivienV | lld:pubmed |
| pubmed-article:19898989 | pubmed:author | pubmed-author:CookDavid MDM | lld:pubmed |
| pubmed-article:19898989 | pubmed:author | pubmed-author:BlethenSandra... | lld:pubmed |
| pubmed-article:19898989 | pubmed:author | pubmed-author:NachtigallLis... | lld:pubmed |
| pubmed-article:19898989 | pubmed:author | pubmed-author:ChangStephenS | lld:pubmed |
| pubmed-article:19898989 | pubmed:author | pubmed-author:SALSA Study... | lld:pubmed |
| pubmed-article:19898989 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19898989 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:19898989 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19898989 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19898989 | pubmed:pagination | 115-22 | lld:pubmed |
| pubmed-article:19898989 | pubmed:dateRevised | 2010-9-28 | lld:pubmed |
| pubmed-article:19898989 | pubmed:meshHeading | pubmed-meshheading:19898989... | lld:pubmed |
| pubmed-article:19898989 | pubmed:meshHeading | pubmed-meshheading:19898989... | lld:pubmed |
| pubmed-article:19898989 | pubmed:meshHeading | pubmed-meshheading:19898989... | lld:pubmed |
| pubmed-article:19898989 | pubmed:meshHeading | pubmed-meshheading:19898989... | lld:pubmed |
| pubmed-article:19898989 | pubmed:meshHeading | pubmed-meshheading:19898989... | lld:pubmed |
| pubmed-article:19898989 | pubmed:meshHeading | pubmed-meshheading:19898989... | lld:pubmed |
| pubmed-article:19898989 | pubmed:meshHeading | pubmed-meshheading:19898989... | lld:pubmed |
| pubmed-article:19898989 | pubmed:meshHeading | pubmed-meshheading:19898989... | lld:pubmed |
| pubmed-article:19898989 | pubmed:meshHeading | pubmed-meshheading:19898989... | lld:pubmed |
| pubmed-article:19898989 | pubmed:meshHeading | pubmed-meshheading:19898989... | lld:pubmed |
| pubmed-article:19898989 | pubmed:meshHeading | pubmed-meshheading:19898989... | lld:pubmed |
| pubmed-article:19898989 | pubmed:meshHeading | pubmed-meshheading:19898989... | lld:pubmed |
| pubmed-article:19898989 | pubmed:meshHeading | pubmed-meshheading:19898989... | lld:pubmed |
| pubmed-article:19898989 | pubmed:meshHeading | pubmed-meshheading:19898989... | lld:pubmed |
| pubmed-article:19898989 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:19898989 | pubmed:articleTitle | Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly. | lld:pubmed |
| pubmed-article:19898989 | pubmed:affiliation | Division of Endocrinology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. salvator@jhmi.edu | lld:pubmed |
| pubmed-article:19898989 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19898989 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:19898989 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19898989 | pubmed:publicationType | Multicenter Study | lld:pubmed |
